Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors
Loading...
Date
Authors
Suarez-Almazor, Maria
Pundole, Xerxes
Abdel-Wahab, Noha
Johnson, Douglas
Gupta, Dipti
Glezerman, Ilya
Cooksley, Tim
Anderson, Ronald
Blidner, Ada Gabriela
Choi, Jennifer
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Abstract
Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents.
Description
Keywords
Arthralgia, Immune checkpoint inhibitor (ICI), Arthritis, Cardiomyopathy, Corticosteroids, Myocarditis, Myositis, Immunomodulation agents, Other immunosuppressive agents, Polymyalgia
Sustainable Development Goals
Citation
Suarez-Almazor, M.E., Pundole, X., Abdel-Wahab, N. et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Support Care in Cancer 28, 6159–6173 (2020). https://doi.org/10.1007/s00520-020-05710-8.